Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expres...
June 03 2019 - 5:00AM
Tartu (Estonia) and Plzen (Czech Republic) June
3, 2019 - Icosagen Cell Factory OÜ, a rapidly growing Estonian
biotechnology company focusing on protein production and in vivo
antibody discovery, and AbCheck s.r.o., a leader in providing
antibody drug discovery, engineering and
optimization services to the biotech
and pharmaceutical industry, today announced that they have
entered into a five-year licensing agreement granting AbCheck
access to Icosagen’s QMCF protein production technology. Under the
terms of the agreement, AbCheck will acquire rights to utilize
Icosagen’s QMCF technology platform for its commercial activities
in antibody discovery.
“AbCheck’s and Icosagen’s partnership has a long
history, and the licensing agreement is a natural next step in our
collaborative effort to bring maximal benefits to our academic and
industry partners and customers,” said Icosagen’s CEO Prof. Mart
Ustav.
“Adding Icosagen’s unique QMCF protein
production technology to our portfolio of versatile in vitro and in
vivo technology solutions will allow us to increase the efficiency
of characterizing the large numbers of antibodies we typically
discover for our partners”, added AbCheck’s Managing Director Dr.
Volker Lang.
About QMCF TechnologyThe QMCF
technology is a new conceptual method of combining several
biological elements to produce proteins for early-stage drug
development processes. The technology provides an advantage
compared to existing technologies, in crucial aspects, such as
timeline, stability and cost-effectiveness. In addition, it is
applicable to the development of test-systems for drug target
screening, large-scale protein production, etc. The QMCF Technology
was developed by Icosagen Cell Factory OÜ during the period
2005-2008. The development of the technology was financed by
Enterprise Estonia. The technology has been granted a patent in
Europe, US, Canada, Japan and Australia.
About Icosagen Cell Factory
OÜIcosagen Cell Factory is a research-driven contract
research provider for biopharmaceutical and biotechnology
industries that deftly adapts to market forces and current trends,
and is always guided by the needs of its customers. Icosagen Cell
Factory OÜ was established in 2005, the company belongs to Icosagen
Group.
About AbCheck s.r.o.AbCheck
s.r.o. discovers and optimizes human antibodies leveraging several
proprietary platforms including in vitro and in vivo technologies
as a service to our partners. We use phage/yeast display libraries
(AbSieve®), mass humanization and antibody optimization (AbAccel®)
to provide high quality leads. Our technology platform can be used
in conjunction with all antibody designs and allows selection of
optimized leads from a huge number of variants. Flexibly adapting
to our partners’ needs, we offer a variety of business models,
including deals without royalties. AbCheck has proven its
capabilities in multiple partnerships throughout the US and Europe.
AbCheck is a wholly owned subsidiary of Affimed GmbH. For more
information, please visit https://abcheckantibodies.com.
Contact Information:
Icosagen
Meelis Kadaja, Director of Business Development E-mail:
meelis.kadaja@icosagen.com
AbCheck
Dr. Volker Lang, Managing DirectorE-mail:
v.lang@abcheckantibodies.eu
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024